Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer
PHASE III STUDY COMPARING TWO DOSES OF INDUCTION CHEMOTHERAPY FOLLOWED BY ALTERNATION OF CHEMOTHERAPY AND RADIOTHERAPY IN LIMITED SMALL CELL LUNG CANCER
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for small cell lung cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of combination chemotherapy using two different doses of cyclophosphamide followed by alternating chemotherapy and radiation therapy in treating patients with small cell lung cancer.
研究概览
详细说明
OBJECTIVES: I. Compare the effect on 2-year disease-free survival of two different doses of cyclophosphamide as part of first induction chemotherapy followed by alternating chemotherapy and chest irradiation in patients with limited stage small cell lung cancer.
OUTLINE: This is a randomized study. Patients are stratified by participating institution. All patients receive 2 courses of induction chemotherapy with doxorubicin, etoposide, cisplatin, and cyclophosphamide. For the first course, one group of patients receives a lower dose of cyclophosphamide than the other group. Both groups receive the same, and still lower, dose of cyclophosphamide during the second course. Beginning 1 week after the completion of induction therapy, patients receive 3 alternating courses each of radiotherapy to the mediastinal and supraclavicular areas delivered over 10-12 days and chemotherapy as in the second course of induction. Each course is initiated after a 1-week rest. Patients receive a final chemotherapy course beginning 4 weeks after the previous chemotherapy course. Patients are followed every 6 months for survival.
PROJECTED ACCRUAL: A total of 280 patients will be entered.
研究类型
注册 (预期的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Angers、法国、49033
- Centre Hospitalier Regional et Universitaire d'Angers
-
Angers、法国、49036
- Centre Paul Papin
-
Bordeaux、法国、33076
- Institut Bergonie
-
Caen、法国、14076
- Centre Regional Francois Baclesse
-
Clamart、法国、92141
- Hôpital Antoine Béclère
-
Corbeil、法国、91100
- Centre Hospitalier Sud Francilien - Site Corbeil
-
Creteil、法国、94010
- Hôpital Intercommunal de Créteil
-
Dijon、法国、21079
- Centre de Lute Contre le Cancer,Georges-Francois Leclerc
-
Dijon、法国、21034
- Hopital De La Trouhade
-
Montbeliard、法国、25209
- C.H. General Andre Boulloche
-
Nantes-Saint Herblain、法国、44805
- CRLCC Nantes - Atlantique
-
Nice、法国、06189
- Centre Antoine Lacassagne
-
Pessac、法国、33604
- Hopital Haut Lévêque
-
Saumur、法国、49403
- C.H. De Saumur
-
Strasbourg、法国、67091
- Hopitaux Universitaire de Strasbourg
-
Toulouse、法国、31052
- Institut Claudius Regaud
-
Vandoeuvre-Les-Nancy、法国、54511
- CHRU de Nancy - Hôpitaux de Brabois
-
Vandoeuvre-les-Nancy、法国、54511
- Centre Alexis Vautrin
-
Villejuif、法国、F-94805
- Institut Gustave Roussy
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS: Histologically proven small cell lung cancer with no distant metastases Size of initial lesion suitable for total irradiation Positive subclavicular nodes allowed No malignant pleural effusion No extension into contralateral lung
PATIENT CHARACTERISTICS: Age: Under 70 Performance status: Karnofsky 60%-100% Hematopoietic: WBC greater than 2,000 Platelets greater than 125,000 Hepatic: Not specified Renal: Creatinine less than 1.1 mg/dL (100 micromoles/L) Cardiovascular: No myocardial infarction within 6 months No other cardiovascular disease that precludes protocol treatment Other: No hearing loss No prior or concurrent malignancy except: Basal cell skin carcinoma In situ carcinoma of the cervix Accessible for follow-up
PRIOR CONCURRENT THERAPY: No prior chemotherapy, radiotherapy, or surgery
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
合作者和调查者
调查人员
- 学习椅：Thierry L. Le Chevalier, MD、Gustave Roussy, Cancer Campus, Grand Paris
研究记录日期
研究主要日期
学习开始
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.